ArticleJournal of neurology2026
Intra-arterial thrombolysis as adjunct to endovascular treatment in acute basilar artery occlusion.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
background and purposeEvidence for intra-arterial thrombolysis (IAT) after endovascular treatment (EVT) remains limited in acute basilar artery occlusion (ABAO), particularly among patients with successful but incomplete reperfusion after EVT. We aimed to evaluate the effectiveness and safety of adjunct IAT following EVT.
methodsThis study was derived from the BASILAR registry. Patients who were treated with and without intra-arterial thrombolysis after successful but incomplete recanalization with a modified thrombolysis in cerebral infarction (mTICI) score of 2b were included. Enrolled patients were divided into EVT plus IAT group and EVT alone group for comparison. The primary effectiveness outcome was the distribution of modified Rankin Scale (mRS) score at 90 days. Safety outcomes included 90-day mortality and symptomatic intracranial hemorrhage within 48 h.
results211 patients were enrolled, 43 (20.4%) received EVT plus IAT. EVT plus IAT was associated with a favorable shift in 90-day mRS distribution [unadjusted common odds ratio (OR) 1.95, 95% confidence interval (CI) 1.00-3.76; P = 0.048; adjusted common OR 2.59, 95% CI 1.15-5.79; P = 0.022]. For safety outcomes, EVT plus IAT was associated with lower 90-day mortality (adjusted OR 0.35, 95% CI 0.14-0.88, P = 0.026), while symptomatic intracranial hemorrhage (sICH) did not differ significantly between groups (P = 0.356). In addition, exploratory analysis demonstrated that baseline stroke severity did not modify the treatment effect of IAT.
conclusionsIn patients with ABAO who achieved successful but incomplete reperfusion after EVT, adjunct IAT was associated with improved functional outcome and lower mortality and may not increase of sICH.
Indexed as
Identifiers
42315640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.